This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Health Winners & Losers: Symmetry Medical

Tuesday proved a mixed day for biotech and health-care stocks. The Amex and Nasdaq biotechnology indices edged down 0.5% and 0.3%, while the Amex pharmaceutical index rose 0.9% to 289.93.

In the health-care space, two diagnostics companies got a lift from new analyst coverage. AspenBio Pharma (APPY - Get Report) climbed 62 cents, or 13.4%, to $5.25 after Lazard Capital initiated coverage with a buy rating. Monogram Biosciences (MGRM) climbed 3 cents, or 2.8%, to $1.09 after JMP Securities initiated coverage with a market outperform rating.

Cardium Therapeutics (CXM) rose on news shares of the San Diego-based medical technology company, which trade on the Amex, have been selected for inclusion in the Russell Microcap Index. The stock rose 17 cents, or 7.7%, to $2.37.

Medical implant company Symmetry Medical (SMA) climbed after reporting first-quarter net income of $4 million, or 11 cents a share, up from $1.6 million, or 5 cents a share, a year ago. Excluding charges, the company earned 20 cents a share on $101.9 million in revenue. Analysts were looking for EPS of 14 cents on revenue of $88.4 million, according to Thomson Reuters data. The stock rose $1.08, or 7.3%, to $15.96.

On the losing side, Invitrogen (IVGN) slid despite an upgrade by JP Morgan from neutral to overweight. The stock fell 78 cents, or 2%, to $39.23.

Goldman downgraded Charles River Laboratories (CRL - Get Report) to neutral from buy based on valuation following the stock's recent strength. The stock is about 13% from Goldman's $13 price target of $73. The stock traded Tuesday as low as 3.5% down, but ended with a loss of just 61 cents, or 0.9%, at $64.27.
This article was written by a staff member of TheStreet.com.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CXM $0.65 -1.52%
APPY $0.44 -1.10%
CRL $70.34 -0.04%
SMA $9.27 -0.43%
AAPL $125.44 0.73%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.06 +5.42 0.26%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs